Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02113449 · ClinicalTrials.gov registry record · Phase 2
Market Potential of Carbon Dioxide Nasal Spray
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
NCT02113449 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 147 participants.
The verdict
NCT02113449, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
Study Summary
Carbon dioxide (CO2) is a naturally occurring gas that readily diffuses across body tissues and membranes. Data from earlier clinical studies conducted in 975 subjects with allergic rhinitis have shown that nasally administered CO2 may provide relief of the associated symptoms. Symptom relief has been shown to occur as soon as 10 minutes after administration, and may persist for four to six hours. This study aims to assess the consumer appeal of a prototype CO2 delivery device, as well as evaluate its perceived effectiveness for nasal congestion. Properly consented subjects who qualify and choose to participate in the clinical study will be administered nasal CO2 under medical supervision, wait a period of 1 hour in clinic, and then be dispensed a device for self-treatment at home. Subjects will return to the clinic on day 7 for final evaluation and completion of assessment questionnaires.
Interventions
- DRUG Carbon Dioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02113449
The ClinicalTrials.gov registry entry for NCT02113449 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carbon Dioxide is the first listed.
NCT02113449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02113449 about?
NCT02113449 is a clinical study titled "Market Potential of Carbon Dioxide Nasal Spray". Carbon dioxide (CO2) is a naturally occurring gas that readily diffuses across body tissues and membranes. Data from earlier clinical studies conducted in 975 subjects with allergic rhinitis have shown that nasally administered CO2 may provide relief of the associated symptoms. Symptom relief has be...
What is the current status of trial NCT02113449?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2013-11. Estimated completion is 2014-02.
What interventions are being tested in trial NCT02113449?
The interventions under investigation include: Carbon Dioxide (DRUG).
Who is sponsoring clinical trial NCT02113449?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.